250 related articles for article (PubMed ID: 9486816)
1. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
Szebeni J; Muggia FM; Alving CR
J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
[TBL] [Abstract][Full Text] [Related]
2. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
[TBL] [Abstract][Full Text] [Related]
3. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
4. Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
D'Errico S; Baldari B; Arcangeli M; Santurro A; Frati P; Fineschi V
Medicine (Baltimore); 2020 Oct; 99(43):e22814. PubMed ID: 33120804
[TBL] [Abstract][Full Text] [Related]
5. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20.
Weiszhár Z; Czúcz J; Révész C; Rosivall L; Szebeni J; Rozsnyay Z
Eur J Pharm Sci; 2012 Mar; 45(4):492-8. PubMed ID: 21963457
[TBL] [Abstract][Full Text] [Related]
6. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
[TBL] [Abstract][Full Text] [Related]
7. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
8. Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
Chowdhury MR; Moshikur RM; Wakabayashi R; Tahara Y; Kamiya N; Moniruzzaman M; Goto M
Mol Pharm; 2018 Jun; 15(6):2484-2488. PubMed ID: 29762034
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Briasoulis E; Karavasilis V; Tzamakou E; Haidou C; Piperidou C; Pavlidis N
Anticancer Drugs; 2002 Jun; 13(5):481-9. PubMed ID: 12045459
[TBL] [Abstract][Full Text] [Related]
10. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.
Theis JG; Liau-Chu M; Chan HS; Doyle J; Greenberg ML; Koren G
J Clin Oncol; 1995 Oct; 13(10):2508-16. PubMed ID: 7595701
[TBL] [Abstract][Full Text] [Related]
11. Alternative formulations of paclitaxel.
Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-induced nail changes: possible role of its vehicle (Cremophor EL).
Minutilli E; Izzo F; Natoli G; Psaila A; Di Filippo F; Terzoli E
Eur J Dermatol; 2006; 16(6):693-4. PubMed ID: 17229616
[No Abstract] [Full Text] [Related]
13. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
[No Abstract] [Full Text] [Related]
14. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Fjällskog ML; Frii L; Bergh J
Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908
[TBL] [Abstract][Full Text] [Related]
15. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
O'Connor TL; Kossoff E
Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
[TBL] [Abstract][Full Text] [Related]
16. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Malingré MM; Schellens JH; Van Tellingen O; Ouwehand M; Bardelmeijer HA; Rosing H; Koopman FJ; Schot ME; Ten Bokkel Huinink WW; Beijnen JH
Br J Cancer; 2001 Nov; 85(10):1472-7. PubMed ID: 11720431
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine.
Liau-Chu M; Theis JG; Koren G
Ann Pharmacother; 1997 Nov; 31(11):1287-91. PubMed ID: 9391679
[TBL] [Abstract][Full Text] [Related]
18. Effect of unpurified Cremophor EL on the solution stability of paclitaxel.
Gogate US; Schwartz PA; Agharkar SN
Pharm Dev Technol; 2009; 14(1):1-8. PubMed ID: 18791935
[TBL] [Abstract][Full Text] [Related]
19. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
Engblom P; Pulkkinen JO; Rantanen V; Hirvonen H; Kulmala J; Grènman R; Grènman S
Eur J Cancer; 1999 Feb; 35(2):284-8. PubMed ID: 10448272
[TBL] [Abstract][Full Text] [Related]
20. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
